MetaCap

Cellectis S.A. (CLLS) vs Journey Medical (DERM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Journey Medical (DERM) has outperformed Cellectis S.A. (CLLS) over the past year, losing 55.8% versus a loss of 80.4%. Over five years, DERM leads with a -61.1% price change compared with -89.4% for CLLS. Journey Medical is the larger company by market cap ($93.2 million vs $92.8 million), about 1.0 times the size, while Cellectis S.A. is growing revenue faster (+75.8% vs +10.2%).

Journey Medical converts more of its revenue into profit, with a net margin of -18.5% versus -92.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CLLS-80.36%DERM-55.76%
+29%-28%-86%
Nov 21, 20251 yearNov 20, 2026
CLLS-89.66%DERM-62.46%
+8%-43%-94%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CLLS versus DERM key metrics
MetricCLLSDERM
Share price$0.9209$3.30
Market cap$92.76M$93.16M
1-day change-7.89%-7.04%
YTD return-80.97%-57.20%
1-year return-80.36%-55.76%
5-year return-89.40%-61.13%
EPS (TTM)$-1.26$-0.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$72.95M$61.86M
Revenue growth (YoY)+75.76%+10.20%
Net income (latest FY)$-67.59M$-11.43M
Gross margin100.00%66.17%
Operating margin-45.34%-13.21%
Net margin-92.66%-18.48%
52-week high$5.45$9.56
52-week low$0.881$3.21
Distance from 52-week high-83.10%-65.46%
Analyst consensusbuystrong_buy
Avg. price target upside+497.24%+286.36%
Average volume115.00K190.39K
Shares outstanding72.73M22.23M
Employees22458
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DERM has outperformed CLLS by 24.6 percentage points over the past year.
  • Journey Medical is more profitable, keeping -18.5 cents of every revenue dollar as net income versus -92.7 cents for Cellectis S.A..
  • Cellectis S.A. grew revenue faster in its latest fiscal year (+75.76% vs +10.20%).

About Cellectis S.A.

CLLS stock →

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).

Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees

About Journey Medical

DERM stock →

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.

Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees

CLLS vs DERM FAQ

Which is bigger, Cellectis S.A. or Journey Medical?

Journey Medical (DERM) is larger, with a market capitalization of $93.16M compared with $92.76M for Cellectis S.A. (CLLS).

Which stock has performed better over the past year, CLLS or DERM?

DERM returned -55.76% over the past 12 months, compared with -80.36% for CLLS (price return, excluding dividends). Past performance does not predict future results.

Are Cellectis S.A. and Journey Medical in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons